Cleerly ISCHEMIA vs Eko Foundation Analysis Software with Transformers (EFAST)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Cleerly ISCHEMIA specializes in analyzing CCTA scans to detect coronary artery ischemia and characterize plaque, offering detailed insights into coronary artery disease. In contrast, EFAST by Eko Health uses AI with digital stethoscopes to identify structural murmurs and atrial fibrillation during routine auscultation. While both are FDA-cleared cardiology AI tools, they address different cardiac conditions and utilize distinct diagnostic modalities.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, particularly when evaluating for ischemia at a vessel level. This tool is ideal for detailed plaque characterization, stenosis severity assessment, and non-invasive fractional flow reserve estimation based on CCTA scans, providing deep insights for personalized diagnosis and treatment planning.

View Cleerly ISCHEMIA →

Choose Eko Foundation Analysis Software with Transformers (EFAST) if…

Choose EFAST if you need real-time, AI-powered assistance during routine physical examinations to screen for common cardiac conditions. This software is best suited for clinicians seeking immediate insights into structural murmurs and atrial fibrillation directly from auscultation, enabling early detection and streamlined documentation at the point of care.

View Eko Foundation Analysis Software with Transformers (EFAST) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly ISCHEMIA Eko Foundation Analysis Software with Transformers (EFAST)
Pricing Unknown Subscription-based, contact for details
Deployment Web-based solution Unknown
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST offers real-time AI analysis during auscultation, seamlessly integrating into a clinician's existing workflow with no additional steps or separate portals, providing immediate insights at the point of care. This direct, real-time feedback during a routine physical exam, coupled with guided exam workflows and EMR integration, makes it highly usable for a broad range of clinicians. Cleerly ISCHEMIA, while offering interactive web reports, is a post-scan analysis tool that requires data transfer via a proxy, suggesting a less immediate and more specialized workflow.

Clinical Value

Tie

Both tools offer significant clinical value by being FDA-cleared and addressing critical cardiac conditions with high accuracy. Cleerly ISCHEMIA provides deep, comprehensive insights into coronary artery disease, including plaque characteristics and non-invasive FFR estimation, which can guide personalized treatment and reduce invasive procedures. EFAST, on the other hand, offers real-time, point-of-care detection of structural murmurs and AFib during routine physical exams, enabling earlier detection and intervention for a broader patient population. Their value is high but in different clinical contexts and stages of patient care.

Pricing & Value

Eko Foundation Analysis Software with Transformers (EFAST)

While both require contacting for specific pricing, EFAST offers more transparency by indicating a subscription-based model, yearly Eko+ membership, and a daily cost equivalent for its associated hardware. This provides a clearer understanding of potential costs for individual practitioners or smaller clinics, and the free trial with stethoscope purchase enhances its perceived value. Cleerly ISCHEMIA's pricing is entirely opaque, stating it varies by provider and requires consultation.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements. Cleerly ISCHEMIA's use of a Cleerly Proxy for data transfer and integration with PowerScribe indicates robust security and workflow integration for imaging-heavy environments. EFAST's cloud-based SaMD deployment with EMR integration and data storage in AWS S3 also signifies readiness for scalable and secure deployment across various clinical settings.

Innovation

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST represents a significant innovation by transforming the traditional stethoscope into an AI-powered diagnostic tool that provides real-time, actionable insights during routine physical exams. Its status as the first FDA-cleared foundation model for cardiovascular AI underscores its pioneering approach. While Cleerly ISCHEMIA offers advanced non-invasive FFR estimation and detailed plaque characterization, EFAST's integration of AI into a ubiquitous point-of-care device for immediate screening holds a broader and more disruptive innovative edge.

Support & Docs

Cleerly ISCHEMIA

Cleerly provides dedicated client support channels with specified hours of operation (Monday to Friday, 10 am ET to 6 pm ET) and a clear process for existing users to request technical assistance via a form. While Eko offers a Help Center and various contact methods, some customer reviews indicate potential inconsistencies in their support responsiveness and shipping issues. Therefore, Cleerly appears to have a more clearly defined and potentially more reliable support structure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly ISCHEMIA Eko Foundation Analysis Software with Transformers (EFAST)
Tool Name Cleerly ISCHEMIA Eko Foundation Analysis Software with Transformers (EFAST)
Company Cleerly Eko Health
Primary Function Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding in personalized diagnosis and treatment planning for heart disease. Assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation, providing real-time, actionable cardiac insights during routine exams.
Input Modality CCTA scans Auscultation (via Eko digital stethoscopes)
Key AI Detections/Analysis Non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment. AI-powered structural murmur detection (93% sensitivity, 91% specificity), AI-powered atrial fibrillation (AFib) detection (95% sensitivity, 94% specificity).
Targeted Conditions Coronary artery ischemia, heart disease Structural murmurs associated with heart disease, atrial fibrillation (AFib)

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Eko Foundation Analysis Software with Transformers (EFAST).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly ISCHEMIA analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, characterize coronary plaque, and assess stenosis severity, aiding in personalized diagnosis and treatment planning for heart disease. EFAST by Eko Health is an AI model that assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation during routine exams, providing real-time cardiac insights.
Cleerly ISCHEMIA requires Coronary Computed Tomography Angiography (CCTA) scans for its AI-enabled analysis. EFAST integrates with Eko digital stethoscopes to provide real-time AI analysis during auscultation, utilizing heart sounds (phonocardiogram, PCG) and electrocardiograms (ECGs) as input.
Cleerly ISCHEMIA is primarily designed for Cardiology and Radiology specialists. EFAST is intended for use by Cardiology, Family Medicine, and Internal Medicine specialists.
EFAST boasts 93% sensitivity and 91% specificity for AI-powered structural murmur detection, and 95% sensitivity and 94% specificity for AI-powered atrial fibrillation detection. Cleerly ISCHEMIA's diagnostic performance for non-invasive determination of coronary artery disease's functional significance has been validated against direct invasive measurement of FFR, demonstrating higher diagnostic accuracy compared to FFRCT and stress testing in studies like CREDENCE.
Cleerly ISCHEMIA offers integration with PowerScribe via API for comprehensive interactive web-based reports. EFAST provides EMR integration for streamlined documentation, along with cloud-based recording and secure storage of exams.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.